You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo

    SBC: Achillion Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (MTB) is probably the most ubiquitous microbial pathogen in the world today infecting one-third of the total population and causing millions of active tuberculosis (TB) cases each year. The economic costs are substantial and more than one million people die of TB infections each year. Before the arrival of antimicrobial therapy, TB wa ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Nanodroplet PCR Lab-Chip for Clinical Pathogen Detection

    SBC: ADVANCED LIQUID LOGIC            Topic: NIAID

    DESCRIPTION (provided by applicant): It is estimated that 2 million health-care associated infections are acquired each year by hospitalized patients resulting in 90,000 deaths and about 4.5 billion in excess health care costs. A large and growing percentage of these infections can be attributed to Staphylococcus aureus and, in particular, to methicillin-resistant S. aureus (MRSA). Rapid PCR-base ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Not Available

    SBC: ADVANCED LIQUID LOGIC            Topic: NHLBI

    Not Available

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Localized Growth Factor Therapy for Surgical Hernia Repair

    SBC: AFFINERGY, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. The incorporation of biocompatible mesh to strengthen the abdominal fascia has largely replaced high-tension suturing techniques in hernia repair. Currently, the preferred biomaterials include durable syntheti ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an adipose-derived stem cell isolation matrix

    SBC: AFFINERGY, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Mesenchymal stem cells (MSCs) are an adult stem cell population, typically isolated from bone marrow aspirates, and are capable of self-renewal, expansion in culture, and differentiation into adipocytes, chondrocytes, and osteoblasts. These cells are being explored for use in tissue engineering applications, such as spinal fusions, bone defect repairs, and cart ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Recombinant expression of a biomaterial-targeting BMP-2 containing a peptide tag

    SBC: AFFINERGY, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): The emergence of biological therapeutics, including cells, peptides, and proteins, has allowed medical science to address a number of unmet clinical needs. Often these agents are extremely potent, specifically activating endogenous signaling cascades to promote well-characterized biochemical and physiological responses. For example, bone morphogenetic protein-2 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a method to multiplex ChIP-SEQ and ChIP-chip experiments

    SBC: AFFOMIX, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): The immediate objective of our research is to generate a method that will enable researchers to multiplex Chromatin ImmunoPreciptation-Sequencing (ChIP-Seq) analysis in a single Next generation DNA sequencing run. In the to-be-developed method: i) a set of antibodies directed against specific DNA-binding proteins are uniquely bar-coded with a DNA 'ZipCode;' ii) ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. High-throughput screening and identification of scFv antibodies against glycosyla

    SBC: AFFOMIX, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): The specific goal of this proposal is to develop a high-throughput method to identify scFv antibodies that recognize post-translationally modified proteins. We propose to complete a proof-of-concept for a new type of affinity screening process based on emulsion, secretion, and capture, which we term ESCape . In the proposed phage ESCape method, E. coli transfo ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. A bifunctional antibody screening system for both phage display and yeast two-hyb

    SBC: AFFOMIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This is a proposal to establish a proof-of-principle for a vector system to isolate high-affinty antibodies through selective rounds in both yeast and Escherichia coli. Antibodies have quickly become extremely useful as therapeutic medicines to treat a wide-variety of disorders. We propose to develop a means of making the discovery of immunotherapeutics faster ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Platelet-based Nanoparticle Therapy for Prostate Cancer

    SBC: ANDROBIOSYS, INC.            Topic: NCI

    The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super paramagnetic iron oxide (SPIO) nanoparticles. The Phase I program showed that SPIO-Stasix particles selecti ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government